Epcoritamab-Lenalidomide Hits Phase 3 PFS Goals: 60% Risk Reduction

For biopharma investors and R&D strategists, the topline data from EPCORE DLBCL-4 validate the combination strategy that AbbVie and Genmab are betting on to move epcoritamab up the treatment ladder. The 60% reduction in risk of progression—with a tight confidence interval and p<0.0001—suggests not just statistical significance but a clinically meaningful effect that could position this non-chemotherapy doublet ahead of rivals. As both companies prepare for regulatory discussions, the focus now turns to potential peak sales, manufacturing scalability, and how this data stacks up against emerging bispecific and next-generation CAR-T candidates.

On June 29, 2026, AbbVie and Genmab announced topline results from the pivotal Phase 3 EPCORE DLBCL-4 trial, demonstrating that the combination of the T-cell engaging bispecific antibody epcoritamab and the immunomodulatory agent lenalidomide achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to the standard-of-care regimen rituximab plus gemcitabine and oxaliplatin (R-GemOx) in adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who had received at least one prior line of therapy. According to the companies, the risk of disease progression or death was reduced by 60% under U.S. censoring rules (hazard ratio [HR] 0.40; 95% CI 0.30–0.55; p<0.0001) and by 56% under ex-U.S. censoring (HR 0.44; 95% CI 0.33–0.60; p<0.0001). The safety profile of the combination was consistent with the known profiles of each drug.

“

censoring rules (hazard ratio [HR] 0.40; 95% CI 0.30–0.55; p<0.0001) and by 56% under ex-U.S.

This announcement marks a significant milestone for the epcoritamab program, which already holds approvals in later lines of DLBCL and follicular lymphoma. The EPCORE DLBCL-4 trial targets a patient population with limited effective options, often facing aggressive disease and poor outcomes after initial treatment failure. R-GemOx, the comparator, is a widely used salvage chemoimmunotherapy regimen, but it offers modest efficacy and significant toxicity. The dramatic PFS benefit reported for the non-chemotherapy doublet represents a potential paradigm shift, substituting chemotherapy with a targeted, fixed-duration immunotherapy approach.

The context is a rapidly evolving treatment landscape for B-cell lymphomas. Epcoritamab, a subcutaneous CD3xCD20 bispecific, belongs to a class that has recently transformed hematological oncology. Competitors include glofitamab (Roche) and mosunetuzumab (Genentech), but epcoritamab’s versatility as a combination partner is a key differentiator. Lenalidomide, an immunomodulatory drug often used in lymphomas, likely potentiates T-cell and NK-cell antitumor activity, complementing epcoritamab’s mechanism. The fixed-duration design (epcoritamab given for a defined period) may offer advantages in reducing treatment burden, limiting cumulative toxicities, and potentially lowering long-term costs compared to indefinite therapies or complex CAR-T infusions.